Literature DB >> 29868331

Atopic Dermatitis: Early Treatment in Children.

Amy Huang1, Christine Cho2, Donald Y M Leung2, Kanwaljit Brar2.   

Abstract

Therapeutic regimens for the treatment and long-term management of AD traditionally had a two-fold objective of decreasing skin inflammation and repairing the defective skin barrier. Essential treatments for AD in children should include topical moisturizers for skin hydration and prevention of flares, topical anti-inflammatory medications (e.g. corticosteroids, calcineurin inhibitors, PDE4 inhibitor), allergen/irritant avoidance, and treatment of skin infections. Treatment regimens should be severity-based, and implemented in a stepwise approach tailored to the individual patient. This stepwise approach includes initial use of emollients, gentle skin care, and escalating to more potent anti-inflammatory treatments as the disease severity increases. Currently available systemic medications should be reserved for the presence of recalcitrance to topical therapies due to associated toxicities. We believe that early treatment of AD is not only essential in treating the skin disease, but also in preventing the development of additional atopic diseases, such as food allergy, asthma and allergic rhinitis. The defective skin barrier of AD permits a route of entry for food and environmental allergens, and upon exposure, keratinocytes secrete TSLP, which activates the TH2 pathway. This TH2 differentiation sets off the atopic march and the subsequent diseases that are seen. This review highlights treatment options and strategies in pediatric AD therapy with an emphasis on early therapy. Supporting evidence on the efficacy and safety of each intervention will be discussed.

Entities:  

Keywords:  allergy; atopic dermatitis; atopic march; corticosteroids; eczema; immunosuppression

Year:  2017        PMID: 29868331      PMCID: PMC5983898          DOI: 10.1007/s40521-017-0140-6

Source DB:  PubMed          Journal:  Curr Treat Options Allergy


  104 in total

1.  Epicutaneous aeroallergen exposure induces systemic TH2 immunity that predisposes to allergic nasal responses.

Authors:  Hiroko Saito Akei; Eric B Brandt; Anil Mishra; Richard T Strait; Fred D Finkelman; Manoj R Warrier; Gurjit K Khurana Hershey; Carine Blanchard; Marc E Rothenberg
Journal:  J Allergy Clin Immunol       Date:  2006-06-09       Impact factor: 10.793

2.  Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.

Authors:  Amy S Paller; Wynnis L Tom; Mark G Lebwohl; Robin L Blumenthal; Mark Boguniewicz; Robert S Call; Lawrence F Eichenfield; Douglass W Forsha; William C Rees; Eric L Simpson; Mary C Spellman; Linda F Stein Gold; Andrea L Zaenglein; Matilda H Hughes; Lee T Zane; Adelaide A Hebert
Journal:  J Am Acad Dermatol       Date:  2016-07-11       Impact factor: 11.527

Review 3.  Efficacy and safety of wet wrap therapy for patients with atopic dermatitis: a systematic review and meta-analysis.

Authors:  G González-López; R M Ceballos-Rodríguez; J J González-López; M Feito Rodríguez; P Herranz-Pinto
Journal:  Br J Dermatol       Date:  2017-05-19       Impact factor: 9.302

4.  The treatment of severe atopic dermatitis in childhood with narrowband ultraviolet B phototherapy.

Authors:  T H Clayton; S M Clark; D Turner; V Goulden
Journal:  Clin Exp Dermatol       Date:  2007-01       Impact factor: 3.470

5.  Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study.

Authors:  Kim A Papp; Thomas Werfel; Regina Fölster-Holst; Jean-Paul Ortonne; Paul C Potter; Yves de Prost; Miles J Davidson; Nathalie Barbier; Hans-Peter Goertz; Carle Paul
Journal:  J Am Acad Dermatol       Date:  2005-02       Impact factor: 11.527

6.  Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies.

Authors:  Lawrence F Eichenfield; Wynnis L Tom; Timothy G Berger; Alfons Krol; Amy S Paller; Kathryn Schwarzenberger; James N Bergman; Sarah L Chamlin; David E Cohen; Kevin D Cooper; Kelly M Cordoro; Dawn M Davis; Steven R Feldman; Jon M Hanifin; David J Margolis; Robert A Silverman; Eric L Simpson; Hywel C Williams; Craig A Elmets; Julie Block; Christopher G Harrod; Wendy Smith Begolka; Robert Sidbury
Journal:  J Am Acad Dermatol       Date:  2014-05-09       Impact factor: 11.527

7.  Mycophenolate mofetil for severe childhood atopic dermatitis: experience in 14 patients.

Authors:  M Heller; H T Shin; S J Orlow; J V Schaffer
Journal:  Br J Dermatol       Date:  2007-05-08       Impact factor: 9.302

8.  Prednisolone vs. ciclosporin for severe adult eczema. An investigator-initiated double-blind placebo-controlled multicentre trial.

Authors:  J Schmitt; K Schäkel; R Fölster-Holst; A Bauer; R Oertel; M Augustin; W Aberer; T Luger; M Meurer
Journal:  Br J Dermatol       Date:  2009-10-26       Impact factor: 9.302

9.  Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy.

Authors:  R M R Hearn; A C Kerr; K F Rahim; J Ferguson; R S Dawe
Journal:  Br J Dermatol       Date:  2008-09       Impact factor: 9.302

Review 10.  Translating Atopic Dermatitis Management Guidelines Into Practice for Primary Care Providers.

Authors:  Lawrence F Eichenfield; Mark Boguniewicz; Eric L Simpson; John J Russell; Julie K Block; Steven R Feldman; Adele R Clark; Susan Tofte; Jeffrey D Dunn; Amy S Paller
Journal:  Pediatrics       Date:  2015-08-03       Impact factor: 7.124

View more
  2 in total

1.  Curcumin Ameliorates Ovalbumin-Induced Atopic Dermatitis and Blocks the Progression of Atopic March in Mice.

Authors:  Sukriti Sharma; Gurupreet S Sethi; Amarjit S Naura
Journal:  Inflammation       Date:  2020-02       Impact factor: 4.092

Review 2.  Recent Developments and Advances in Atopic Dermatitis: A Focus on Epidemiology, Pathophysiology, and Treatment in the Pediatric Setting.

Authors:  Lawrence F Eichenfield; Stephen Stripling; Selwyn Fung; Amy Cha; Andryann O'Brien; Lawrence A Schachner
Journal:  Paediatr Drugs       Date:  2022-06-13       Impact factor: 3.930

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.